Atossa Genetics Inc (ATOS)

NASDAQ
2.42
+0.11(+4.76%)
Pre Market
2.50
+0.08(+3.31%)
- Real-time Data
  • Volume:
    14,368,740
  • Bid/Ask:
    2.49/2.50
  • Day's Range:
    2.19 - 2.63

ATOS Overview

Prev. Close
2.42
Day's Range
2.19 - 2.63
Revenue
-
Open
2.26
52 wk Range
0.811 - 5.04
EPS
-1.81
Volume
14,368,740
Market Cap
292.39M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
11,606,779
P/E Ratio
-
Beta
2.23
1-Year Change
24.1%
Shares Outstanding
120,824,368
Next Earnings Date
May 18, 2021
What is your sentiment on Atossa Genetics Inc?
or
Market is currently closed. Voting is open during market hours.

Atossa Genetics Inc News

  • AVXL, GME, ATOS and BTU among midday movers
    • BySeeking Alpha-

    Gainers: ATA Creativity Global (NASDAQ:AACG) +204%.Anavex Life Sciences (NASDAQ:AVXL) +81%.Lizhi (NASDAQ:LIZI) +76%.CPS Technologies (NASDAQ:CPSH) +48%.Annovis Bio...

  • ATOS, EXPR, SOL and UAVS among midday movers
    • BySeeking Alpha-

    Gainers: Aemetis (NASDAQ:AMTX) +105%.Express (NYSE:EXPR) +98%.MingZhu Logistics (NASDAQ:YGMZ) +50%.TS Innovation Acquisitions (TSIA) +45%.IZEA Worldwide (NASDAQ:IZEA) +43%.Orbital...

Atossa Genetics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuySell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral

Atossa Genetics Inc Company Profile

Atossa Genetics Inc Company Profile

Employees
4

Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).

Read More
  • Would FDA consider emergency use of nasal spray given the seriousness of the covid?
    0
    • https://biopharmajournal.com/2021/05/03/atossa-therapeutics-inc-nasdaqatos-commences-treatment-of-a-patient-with-ovarian-cancer-using-its-proprietary-drug-endoxifen/
      0
      • @GulfCoastGold - new to options. Which trading platform do you use for naked options trading/
        0
        • I just learned how to short so sorry this is just part of the requirement. THIS IS GOING TO ZERO! GUARANTEED!!! TRASH STOCK! GO BUY DOGE!
          10
          • Lmaoooo leave it to the dogecoin people to be spreading info that they themselves know is false🤣
            0
          • I'm amazed at the 5 people that can't recognize a joke lol
            0
        • Look at the chart this is going back to $1.45 easy. This will be a quick profit for me.
          8
          • Yeah, with a price target of $6.38 i dont think anyone should be concerned with where the price is at right now.
            0
        • Pasie pasiencia
          0
          • Trash stock
            4
            • Dr. Quay is a brilliant mind and he is exposing the fact hay Covid was created in a lab amd has explained it on depth. Who better than to creat a spray to counter it than a scientist who inderstands its origins! But keep on mind this is a long term hold! I see $8 this year and next year with more results from Phase 2 on Endoxiphen and a phase 3 potentially begining tjis could really ho into the 20’s and on 2023 maybe we habe a $150 stock if....they arent bought out before them or partner with a big time pharma to produce their drugs!
              4
              • 12.04 1.87 !
                1
              • 1
              • Jobir Avezovenjoy your laugh now! In the next 18 months lets see who laughs last!
                0
            • Heard they have a Covid treatment in there pipeline of drugs!
              1
              • Better than expected results will trigger a rally from tomorrow on.
                1
                • Why tomorrow?
                  0
                • Sorry just realized that your was a very old message
                  0
              • ??????
                0
                • look at jul call option
                  0
                  • as i see by open interest call/put the price between 4 and 9
                    0
                  • it means close ur eyes n just buy now...lol
                    0
                • Load up cheap shares
                  0
                  • 0.8 new stop
                    3
                    • Joseph Simone good article thanks. i'm ready to wait 12 month
                      0
                  • Wish Stock is undervalued, just bought more shares. Please share with your friends we have to bring wish to a higher level.
                    1
                    • the price has falled 22.03 because of 50 million shares direct offering
                      0
                      • Gregory Aizenbergapparently it does Greg. I often thought it did not but apparently it does.
                        0
                      • thanks Joseph! please look on Graybug Vision Inc (GRAY)
                        0
                      • i tried to open - only for US residents unfortunately
                        0
                    • https://biopharmajournal.com/2021/03/18/atossa-therapeutics-pleased-after-fda-gives-it-a-safe-to-proceed-letter-to-continue-ovarian-cancer-treatment/
                      0
                      • https://biopharmajournal.com/2021/03/18/atossa-therapeutics-pleased-after-fda-gives-it-a-safe-to-proceed-letter-to-continue-ovarian-cancer-treatment/
                        1
                        • If FDA approves Nasal spray, we are looking at at least 10 dollars for this stock
                          0
                          • Read somewhere FDA is considering emergency approval for use of covid 19 nasal spray in light of surge of covid cases
                            0
                            • If there’s no adverse symptoms during the P2, there’s a chance for a emergency use of the spray
                              0
                            • Joseph Simone i'm sitting tight and i'd like to buy dip already have 1500 pcs
                              0
                            • Joseph Simone  today 1000 more
                              0
                          • Rocket...
                            0
                            • test
                              0
                              • In @ $2,70. Let's see what will happen in some days.
                                0
                                • With this news, I think that this stock can reach $5 in 1 week.Thank you Joseph for the suggestion.
                                  0
                                • Augusto Silvajust be patient. I see no reason this is not an $8 stock this year and potentially an even bigfer winner in 2022!
                                  0
                                • Augusto Silvathis Dr. Quay is a brilliant mind and he is exposing the fact hay Vobid was created in a lab amd has explained it on depth. Who better than to creat a spray to counter it than a scientist who inderstands its origins!
                                  0
                              • depends what your looking for
                                0
                                • Bought today 1000 shares at 3.00. May be I did mistake.
                                  0
                                  • no
                                    0
                                  • happens to me all the time.
                                    0
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.